| LncRNA Information | ||||||
|---|---|---|---|---|---|---|
| ID | EL0588 | Name | HOXA-AS2 | Aliases | HOXA3as | |
| Species | Homo sapiens | Chromosome | 7 | Start site | 27107777 | |
| End site | 27134302 | Chain | plus | Exon NO. | 4 | |
| Assembly | Ensembl Release 89 | Class | antisense | NCBI accession | NR_122069 | |
| Ensembl | ENSG00000253552 | Sequence | ||||
| Disease | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Disease | Method | Sample | Expression pattern | Dysfunction type | Description | PMID | Source | ||
| gastric cancer | microarray, qPCR, Western blot, Luciferase reporter assay etc. | gastric cancer tissue, cell lines (BGC823, SGC7901, AGS) | up-regulated | interaction | Here, we reported that HOXA cluster antisense RNA2 (HOXA-AS2), a 1048bp RNA, was upregulated in GC. Increased HOXA-AS2 expression in GC was associated with larger tumor size and higher clinical stage; patients with higher levels of HOXA-AS2 expression had a relatively poor prognosis. HOXA-AS2 could be an oncogene for GC partly through suppressing P21, PLK3, and DDIT3 expression; HOXA-AS2 may be served as a candidate prognostic biomarker and target for new therapies in human GC. | 26384350 | Lnc2Cancer | ||
| Interaction | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Interaction target | Level of interaction | Type of interaction | Description | PMID | Source | ||||
| EZH2 (enhaner of zeste homolog 2) | RNA-Protein | binding | HOXA-AS2 could epigenetically repress the expression of P21, PLK3, and DDIT3 via binding with EZH2 (enhaner of zeste homolog 2), a key component of PRC2 | 26384350 | |||||
| P21/PLK3/DDIT3 | RNA-Protein | regulation | HOXA-AS2 could epigenetically repress the expression of P21, PLK3, and DDIT3 via binding with EZH2 (enhaner of zeste homolog 2), a key component of PRC2 | 26384350 | |||||